These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2578830)

  • 1. Anticomplementary activity of dextran derivatives.
    Mauzac M; Maillet F; Jozefonvicz J; Kazatchkine MD
    Biomaterials; 1985 Jan; 6(1):61-3. PubMed ID: 2578830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular weight dependency of the acquired anticomplementary and anticoagulant activities of specifically substituted dextrans.
    Crepon B; Maillet F; Kazatchkine MD; Jozefonvicz J
    Biomaterials; 1987 Jul; 8(4):248-53. PubMed ID: 2444275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.
    Kazatchkine MD; Fearon DT; Metcalfe DD; Rosenberg RD; Austen KF
    J Clin Invest; 1981 Jan; 67(1):223-8. PubMed ID: 6778897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant activity of dextran derivatives. Part II: Mechanism of thrombin inactivation.
    Fischer AM; Mauzac M; Tapon-Bretaudiere J; Jozefonvicz J
    Biomaterials; 1985 May; 6(3):198-202. PubMed ID: 2408688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytic study of the differential anticomplementary effects of dextran sulphate and heparin in the assay for the mouse alternative pathway.
    Klerx JP; Van Dijk H; Van der Maaden WJ; Willers JM
    Int Arch Allergy Appl Immunol; 1985; 78(2):182-9. PubMed ID: 2412967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the formation of the human C-3 amplification convertase of complement by polyelectrolytes.
    Kazatchkine MD; Maillet F; Fischer E; Glotz D
    Agents Actions; 1981 Dec; 11(6-7):645-6. PubMed ID: 6918183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticomplementary activity of boswellic acids--an inhibitor of C3-convertase of the classical complement pathway.
    Kapil A; Moza N
    Int J Immunopharmacol; 1992 Oct; 14(7):1139-43. PubMed ID: 1452399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition by heparin and derivatized dextrans of Staphylococcus aureus adhesion to fibronectin-coated biomaterials.
    Vaudaux P; Avramoglou T; Letourneur D; Lew DP; Jozefonvicz J
    J Biomater Sci Polym Ed; 1992; 4(2):89-97. PubMed ID: 1283081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin.
    Weiler JM; Yurt RW; Fearon DT; Austen KF
    J Exp Med; 1978 Feb; 147(2):409-21. PubMed ID: 624904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of substituted dextran derivative on complement activation in vivo.
    Thomas H; Maillet F; Letourneur D; Jozefonvicz J; Kazatchkine MD
    Biomaterials; 1995 Oct; 16(15):1163-7. PubMed ID: 8562793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-complement activity of oleanolic acid: an inhibitor of C3-convertase of the classical complement pathway.
    Kapil A; Sharma S
    J Pharm Pharmacol; 1994 Nov; 46(11):922-3. PubMed ID: 7897600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro.
    Linhardt RJ; Rice KG; Kim YS; Engelken JD; Weiler JM
    J Biol Chem; 1988 Sep; 263(26):13090-6. PubMed ID: 3417651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-like activity of insoluble sulphonated polystyrene resins. Part I: Influence of the surface density, nature and binding of substituted anionic groups.
    Kanmangne FM; Labarre D; Serne H; Jozefowicz M
    Biomaterials; 1985 Sep; 6(5):297-302. PubMed ID: 4052545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method for the determination of the anticomplementary activity of heparin and related compounds.
    WALTON KW; ELLIS HA; TAYLOR CE
    Br J Exp Pathol; 1957 Jun; 38(3):237-47. PubMed ID: 13436718
    [No Abstract]   [Full Text] [Related]  

  • 15. [Complement inhibitors and their action mechanism].
    Takada A; Takada Y
    Nihon Rinsho; 1979 May; 37(5):977-82. PubMed ID: 381729
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anticomplement activity of native dextrans].
    Preobrazhenskaia ME; Danilova NA
    Vopr Med Khim; 1977; (3):385-91. PubMed ID: 888406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant activity of dextran derivatives. Part I: Synthesis and characterization.
    Mauzac M; Jozefonvicz J
    Biomaterials; 1984 Sep; 5(5):301-4. PubMed ID: 6207865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy between two active sites of human complement receptor type 1 (CD35) in complement regulation: implications for the structure of the classical pathway C3 convertase and generation of more potent inhibitors.
    Krych-Goldberg M; Hauhart RE; Porzukowiak T; Atkinson JP
    J Immunol; 2005 Oct; 175(7):4528-35. PubMed ID: 16177096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulant hydrogels derived from crosslinked dextran. Part I: Synthesis, characterization and antithrombic activity.
    Aubert N; Mauzac M; Jozefonvicz J
    Biomaterials; 1987 Jan; 8(1):24-9. PubMed ID: 2435328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of host from its own complement by membrane-bound complement inhibitors: C3 convertase inhibitors vs membrane attack complex inhibitors.
    Kinoshita T
    Res Immunol; 1996 Feb; 147(2):100-3. PubMed ID: 8792468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.